Results 21 to 30 of about 590 (119)

Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice [PDF]

, 2023
BACKGROUND: Evidence about tralokinumab treatment for moderate-to-severe atopic dermatitis (AD) in daily practice is limited. AIM: To report the first evidence, to our knowledge, from daily practice of treatment with tralokinumab in patients with AD ...
Shareef, Madena, Schlösser, Anne R., Nijsten, Tamar E.C., Olydam, Jill, Tamar E C Nijsten, Hijnen, Dirk Jan; id_orcid, Jill Olydam, Madena Shareef, Anne R Schlösser, Dirk Jan Hijnen   +9 more
core   +1 more source

Tralokinumab in Atopic Dermatitis: A Profile of Its Use

, 2022
DeclarationsFunding The preparation of this review was not supported by any external funding.Authorship and Conflict of interest Hannah Blair is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest.
Hannah A. Blair (6846307)
core   +1 more source

Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis:results from five tralokinumab clinical trials

, 2021
Background: Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds with high affinity to interleukin-13, effectively reduces moderate-to-severe atopic dermatitis (AD) when given every 2 weeks.
Boguniewicz, M., Thyssen, J. P., Imafuku, S., Zachariae, R., Wollenberg, A., Beck, L. A., Olsen, C. K., de Bruin Weller, M., Simpson, E. L., L.A. Beck, J.P. Thyssen, M. Boguniewicz, C.K. Olsen, A. Wollenberg, M. de Bruin Weller, R. Zachariae, E.L. Simpson, S. Imafuku   +17 more
core   +1 more source

The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents

, 2023
Atopic dermatitis (AD) is an inflammatory skin disease that frequently occurs in adolescents. Although there are many treatment options, the challenge for clinicians is finding an effective long-term drug for AD with a favorable safety profile.
Adaora R Ewulu, Prajapati, Stuti, Ewulu, Adaora R., Feldman, Steven R., Stuti Prajapati, Steven R Feldman   +5 more
core   +1 more source

Tralokinumab: First Approval

, 2021
DeclarationsFunding The preparation of this review was not supported by any external funding.Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Sean Duggan (4873369)
core   +1 more source

Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors

, 2023
: Background: Tralokinumab has been recently approved for the management of moderate-to-severe atopic dermatitis (AD). Despite its effectiveness and safety have been widely reported, there are no studies investigating factors that may affect clinical ...
Potestio, Luca, Napolitano, Maddalena, Patruno, Cataldo   +2 more
core   +1 more source

Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study. [PDF]

, 2023
Tralokinumab, the first fully human monoclonal antibody that binds specifically to interleukin-13, was safe and effective for treating atopic dermatitis (AD) in clinical trials, but real-life experience is still limited.
Ghislain, Pierre-Dominique, Baeck, Marie, Coster, Alison, Zoghaib, Samer, De Greef, Axel, Damsin, Thomas, Jacobs, Marie-Claude, de Halleux, Céline, Bulinckx, Audrey, Suys, Erwin   +9 more
core   +1 more source

Over two years' experience with tralokinumab for moderate to-severe atopic dermatitis : three clinical case studies

, 2023
Tralokinumab is an anti-interleukin-13 monoclonal antibody approved in several geographical regions for the treatment of moderate-to-severe atopic dermatitis.
Halpern, James, Sarapuddin, Ben, Cuell, Alexis, Akbar, Faraz   +3 more
core  

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study

, 2015
International audienceOBJECTIVE:Interleukin-13 (IL-13) has been implicated as a key driver of UC. This trial evaluates the efficacy and safety of tralokinumab, an IL-13-neutralising antibody, as add-on therapy in adults with moderate-to-severe UC despite
Uebel, Peter, Brandt, Wolfgang, Hansen, Mark Berner, Rudziński, Janusz, Knutsson, Mikael, Dupas, Jean-Louis, Lukas, Milan, Danese, Silvio, Bouhnik, Yoram, Keshav, Satish, Kleczkowski, Dariusz, Peyrin-Biroulet, Laurent, Erlandsson, Fredrik, Dupas JL, Erlandsson F, Keshav S, Peyrin-Biroulet L, Lukas M, Uebel P, Rudzinski J, Danese S, Knutsson M, Kleczkowski D, Brandt W, Hansen MB, Bouhnik Y   +25 more
core   +1 more source

Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program

, 2018
Tralokinumab, a fully human IgG4 monoclonal antibody, specifically neutralizes IL-13. The ATMOSPHERE clinical development program comprised four randomized, placebo-controlled clinical trials and an open-label study that aimed to assess the efficacy and
Millie Wang, Karin Bowen, Gene Colice, Reynold A Panettieri Jr, Martin Braddock   +4 more
core   +1 more source